FDA Grants Accelerated Approval to Bizengri, Merus' Targeted Therapy for NRG1-Fusion Positive Biliary Tract Cancer
First-in-Class NRG1-Fusion Targeted Therapy Approved
FDA has approved Bizengri (zenocutuzumab-zbco), developed by Merus N.V. and commercialized by Partner Therapeutics, for the treatment of NRG1-fusion positive biliary tract cancer. NRG1 (Neuregulin 1) fusion mutations drive cell proliferation and contribute to cancer development, but effective targeted therapies have been lacking, resulting in poor prognosis. Bizengri is a bispecific antibody that targets HER2 and HER3 receptors, offering a novel mechanism to block NRG1 signaling. This approval provides the first precision medicine option targeting a specific genetic alteration for patients with this rare form of biliary tract cancer.
Expedited Review Supported by Regulatory Program
The approval was expedited through the FDA's 'Commissioner's National Priority Voucher (CNPV)' pilot program. The CNPV program reduces the review period from the standard 10-12 months to 1-2 months, and Bizengri is the seventh approval under this program. The FDA utilized accelerated approval to facilitate the rapid market entry of this innovative therapy, demonstrating the agency's flexibility in addressing unmet needs in rare diseases. This is a positive signal for other biotech companies with rare disease pipelines, potentially shortening their regulatory timelines.
Efficacy Demonstrated in Phase 2 eNRGy Trial
The approval of Bizengri is based on data from the eNRGy trial, a multi-center, open-label Phase 2 study. In a cohort of patients with NRG1-fusion positive biliary tract cancer who had failed prior systemic therapy, Bizengri demonstrated an objective response rate (ORR) of 36.8%, with a duration of response (DOR) ranging from 2.8 to 12.9 months. Despite the rarity of this patient population, representing only about 0.5% to 0.8% of all biliary tract cancers, the efficacy was clearly demonstrated, leading to approval. As a condition of the accelerated approval, the companies must conduct a confirmatory Phase 3 trial to further demonstrate clinical benefit.
Commercial Partnership and Opportunity in the Rare Cancer Market
Merus entered into a U.S. exclusive license agreement with Partner Therapeutics in December 2024 for the commercialization of Bizengri in the United States. Under the agreement, Partner Therapeutics will be responsible for U.S. commercialization, and Merus will receive an upfront payment, milestone payments, and royalties in the high single-digit to low double-digit percentage range of net sales. The global biliary tract cancer market is estimated at $660 million to $750 million by 2026, and Bizengri is expected to command a strong pricing position due to its unique mechanism of action. This represents a successful win-win strategy between a platform-focused biotech and a commercialization-focused company.
First-Mover Advantage and Competitive Pipeline
Bizengri has secured a strong first-mover advantage as the first targeted therapy for NRG1 in biliary tract cancer. While Seribantumab is in clinical development, and Afatinib has been used off-label, Bizengri is likely to dominate the market in terms of efficacy and regulatory approval. This approval is also expected to drive the adoption of RNA-based fusion testing, a companion diagnostic, which will further stimulate the growth of the precision diagnostics market.
The FDA's accelerated approval of Bizengri (zenocutuzumab-zbco) signifies the arrival of the first-in-class targeted therapy for NRG1-fusion positive biliary tract cancer, a market estimated at $660 million to $750 million annually. This approval provides Bizengri with a significant first-mover advantage over potential competitors. In the short term, Merus N.V. will benefit from milestone payments and royalties from Partner Therapeutics, strengthening its financial position and accelerating the development of its pipeline. In the medium to long term, the success of Bizengri will depend on the successful completion of the confirmatory Phase 3 trial, which will be crucial in maintaining its market position against competitors like Seribantumab. Furthermore, the FDA's use of the CNPV program to expedite the review process sets a precedent for other biotech companies targeting rare genetic mutations, potentially influencing their regulatory strategies and fundraising efforts.